FSR is proud to announce the launch of the Ignore No More: ACTe Now! (Advance Clinical Trials for Equity in Sarcoidosis) campaign. The goals of this campaign are to increase representation of Black American sarcoidosis patients in clinical trials, raise awareness of...
FSR is pleased to announce that the FSR Sarcoidosis Research Fellowship for 2022-2024 is being awarded to Dr. Nancy Lin from National Jewish Health, a Founding Member of the FSR Global Sarcoidosis Clinic Alliance, for her project, “Defining MicroRNA Biomarkers...
Foundation for Sarcoidosis Research (FSR) announces the launch of the FSR Global Sarcoidosis Clinic Alliance, a groundbreaking initiative that will have a worldwide impact on advancing sarcoidosis research and improving the lives of those with sarcoidosis through...
SUNY Upstate Medical University Auyon Ghosh MD, MPH, to be presented with $50,000 Partnership Research Grant from American Thoracic Society and Foundation for Sarcoidosis Research The Foundation for Sarcoidosis Research (FSR), the leading international nonprofit...
FSR is pleased to announce the 2021 Small Research Grant Awardees. As part of our mission, FSR accelerates sarcoidosis research through fellowships, small grants, and large grant programs, and has dedicated over $5M million for worldwide sarcoidosis research since...
On September 13, 2021, aTyr Pharma announced positive results from their Phase1b/2a clinical trial for ATYR1923 in pulmonary sarcoidosis. FSR is proud to have supported this clinical trial. The trial demonstrated that ATYR1923 was safe and well-tolerated, 33%...
The Foundation for Sarcoidosis Research (FSR) is pleased to announce the Foundation for Sarcoidosis Research Fellowship Grant for 2021-2023 is being awarded to Dr. Paula Berreras from Johns Hopkins University Hospital for her project, “Discovering pathogens in...
Authors: Arindam Singha, MD1; Tricha Shivas, MBe2 ; Elliot D. Crouser, MD1 Since it was declared a global pandemic in March of 2020, the coronavirus disease 2019 (COVID-19) has affected over 100 million lives globally. It has been demonstrated that patients...
Early Investigator Grant Opportunity The Foundation for Sarcoidosis Research (FSR) is seeking proposals from US-based early-stage investigators for a grant that provides support for a collaborative and translational research project that will positively impact...
Xentria Inc. has recently announced they received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for their intravenous TNF-inhibitor, XTMAB-16. The FDA grants orphan status to drugs being developed to treat those with rare diseases. This...
